Obermatt
See Similar Stocks →

Ilsung IS

KSC:003120 · KR7003120003
PharmaceuticalsSmall

360

59
Medium confidence — indicative
Profit price1
Owner Earnings Yield59
Dividend Yield1
Price/Sales17
Price/Book89
Return on Capital55
Cash Return on Capital59
Return on Equity62
EBIT Margin33
Gross Profitability26
Cash Conversion38
Accruals44
Owner Earnings Margin76
Sales growth27
Profit Growth43
Owner Earnings Growth51
Reinvestment24
Price momentum69
Debt load100
Refinancing26
Debt Payback100
Liquidity1
Analyst ratings—
Expectations trend—
Market mood4
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Ilsung IS doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeKOSE
Employees7
Websiteilsungis.com
ISINKR7003120003
Last UpdateApr 2, 2026
Indices
KOSPI (South Korea)
Themes
DiabetesCardiovascularPain ManagementRespiratoryCentral Nervous SystemNeurologyPharmaceutical

Description

Analysis

Middle-of-the-road

Ilsung Is Co., Ltd. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is expensive. You pay 44.5× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone.

The trajectory is moderate and the balance sheet is adequate. The company scores 6/20 on our value-creation score: not creating value.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
17
—
—
—
Price/Earnings
1
—
—
—
Price/Book
89
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
14
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Ilsung IS with its peers
Kukje Pharma
KSC:002720
43
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Hanall Biopharma
KSC:009420
30
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Dongwha Pharm
KSC:000020
44
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Hana Pharm
KSC:293480
88
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Reyon Pharmaceutical
KSC:102460
16
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Whanin Pharm
KSC:016580
99
CountrySouth Korea
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →